Free Trial

Protagonist Therapeutics (PTGX) Stock Price, News & Analysis

Protagonist Therapeutics logo
$51.07 +0.11 (+0.22%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$50.60 -0.48 (-0.93%)
As of 08/8/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Protagonist Therapeutics Stock (NASDAQ:PTGX)

Key Stats

Today's Range
$50.49
$51.41
50-Day Range
$49.70
$56.64
52-Week Range
$33.31
$60.60
Volume
719,043 shs
Average Volume
640,986 shs
Market Capitalization
$3.18 billion
P/E Ratio
72.96
Dividend Yield
N/A
Price Target
$67.20
Consensus Rating
Buy

Company Overview

Protagonist Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
59th Percentile Overall Score

PTGX MarketRank™: 

Protagonist Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 410th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Protagonist Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Protagonist Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Protagonist Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Protagonist Therapeutics are expected to decrease in the coming year, from $2.43 to ($0.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Protagonist Therapeutics is 72.96, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.86.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Protagonist Therapeutics is 72.96, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.01.

  • Price to Book Value per Share Ratio

    Protagonist Therapeutics has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.93% of the outstanding shares of Protagonist Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Protagonist Therapeutics has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Protagonist Therapeutics has recently decreased by 8.17%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Protagonist Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Protagonist Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.93% of the outstanding shares of Protagonist Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Protagonist Therapeutics has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Protagonist Therapeutics has recently decreased by 8.17%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Protagonist Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Protagonist Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    2 people have searched for PTGX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Protagonist Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Protagonist Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,020,877.00 in company stock.

  • Percentage Held by Insiders

    Only 4.90% of the stock of Protagonist Therapeutics is held by insiders.

  • Percentage Held by Institutions

    98.63% of the stock of Protagonist Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Protagonist Therapeutics' insider trading history.
Receive PTGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PTGX Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Protagonist (PTGX) Q2 Revenue Falls 26%
See More Headlines

PTGX Stock Analysis - Frequently Asked Questions

Protagonist Therapeutics' stock was trading at $38.60 at the beginning of the year. Since then, PTGX stock has increased by 32.3% and is now trading at $51.07.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) posted its earnings results on Wednesday, August, 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.02. The business had revenue of $5.55 million for the quarter, compared to the consensus estimate of $8.32 million. Protagonist Therapeutics had a net margin of 24.88% and a trailing twelve-month return on equity of 8.12%.

Protagonist Therapeutics (PTGX) raised $70 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

Top institutional shareholders of Protagonist Therapeutics include Geode Capital Management LLC (2.33%), Jupiter Asset Management Ltd. (0.65%), Bank of New York Mellon Corp (0.63%) and Moody Aldrich Partners LLC (0.28%). Insiders that own company stock include Dinesh V Ph D Patel, Suneel Gupta, Arturo Md Molina, Asif Ali and William D Waddill.
View institutional ownership trends
.

Shares of PTGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Protagonist Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
8/06/2025
Today
8/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PTGX
CIK
1377121
Fax
N/A
Employees
120
Year Founded
2006

Price Target and Rating

High Price Target
$80.00
Low Price Target
$38.00
Potential Upside/Downside
+31.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.70
Trailing P/E Ratio
72.96
Forward P/E Ratio
21.02
P/E Growth
N/A
Net Income
$275.19 million
Net Margins
24.88%
Pretax Margin
25.71%
Return on Equity
8.12%
Return on Assets
7.41%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.97
Quick Ratio
17.26

Sales & Book Value

Annual Sales
$209.18 million
Price / Sales
15.19
Cash Flow
$4.52 per share
Price / Cash Flow
11.31
Book Value
$10.74 per share
Price / Book
4.76

Miscellaneous

Outstanding Shares
62,211,000
Free Float
59,163,000
Market Cap
$3.18 billion
Optionable
Optionable
Beta
2.33

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:PTGX) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners